查看文章

Even in the era of these newer drugs, upfront autologous hematopoietic stem cell transplantation (AHCT) continues to confer benefits and remains a preferred strategy in transplant-eligible multiple myeloma (MM) patients [1]. Despite these effective interventions, MM invariably relapses after a period. The treatment landscape in relapsed MM continues to change with the introduction of several new agents. A second salvage AHCT (AHCT2) is another option for MM relapsing after a prior autotransplant. However, its use varies widely given the lack of modern randomized studies, and the availability of several different options in this therapeutic space [2]. We sought to assess the contemporary utility, safety, and clinical benefits of AHCT2 using the Center for International Blood and Marrow Transplant Research®(CIBMTR®) data. Patients who underwent AHCT2 for MM between 2010 and 2015 in the US and Canada …